Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

In several phase II-trials encouraging tumour responses rates in advanced metastatic melanoma (stage IV; AJCC-classification) have been reported for the application of biochemotherapy containing interleukin 2. This study was designed to compare the efficacy of therapy with dacarbazine (DTIC) and int...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2001
Matèries:
Regular Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363865/
https://ncbi.nlm.nih.gov/pubmed/11308250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1731
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars